IP Library Granted Patent US 8,853,175
Granted Patent B2
US 8,853,175 · App. 13/346,455 · Granted Oct 7, 2014

Phenethylsulfone isoindoline derivatives and their use

Inventors: Gondi Kumar (Basking Ridge, NJ); Hon-Wah Man (Princeton, NJ); Roger S. C. Chen (Edison, NJ); George W. Muller (Rancho Santa Fe, CA); Anthony J. Frank (Easton, PA)
Assignee: Celgene Corporation
C07D209/48A61K31/7056A61K31/4035C07H15/203
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,853,175
App. No.
13/346,455
Granted
Oct 7, 2014
Kind
B2
Abstract

Provided are phenethyl isoindoline compounds, and pharmaceutically acceptable salts, solvates, or stereoisomers thereof. Methods of use and pharmaceutical compositions of these compounds are also disclosed.

Claims (25)

1. A pharmaceutical composition comprising a compound of formula (I):

or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:

R 1 is hydrogen or —C(O)R 5 ;

R 2 is hydrogen, methyl, or glucuronide (gluc);

R 3 is hydrogen, ethyl, or gluc;

R 4 is hydrogen or hydroxyl;

R 5 is straight chain alkyl containing 1 to 6 carbon atoms, optionally substituted with —OR 6 ; and

R 6 is hydrogen or gluc;

when R 1 is —C(O)R 5 and R 5 is unsubstituted methyl:

R 2 is hydrogen and R 3 is ethyl;

R 2 is hydrogen and R 3 is hydrogen;

R 2 is gluc and R 3 is ethyl;

R 2 is methyl and R 3 is gluc; or

R 2 is methyl and R 3 is hydrogen;

with the proviso that when R 2 is methyl, R 3 is ethyl and R 4 is hydrogen, then R 1 cannot be hydrogen.

2. The pharmaceutical composition of claim 1 , wherein R 1 is —C(O)R5.

3. The pharmaceutical composition of claim 2 , wherein R 5 is methyl, optionally substituted with —OH.

4. The pharmaceutical composition of claim 2 , wherein R 5 is methyl, optionally substituted with —O-gluc.

5. The pharmaceutical composition of claim 1 , wherein R 1 and R 2 are both hydrogen.

6. The pharmaceutical composition of claim 1 , wherein R 3 is ethyl.

7. The pharmaceutical composition of claim 1 , wherein R 1 is hydrogen.

8. The pharmaceutical composition of claim 7 , wherein R 3 is ethyl and R 4 is hydroxyl.

9. The pharmaceutical composition of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt or solvate thereof.

10. A method of treating or managing a disease or disorder comprising administering to a patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein the disease or disorder is cancer, pain, macular degeneration, a skin disease, a pulmonary disorder, a parasitic disease, an immunodeficiency disorder, a CNS disorder, CNS injury, atherosclerosis, dysfunctional sleep, or hemoglobinopathy.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2019
From: CELGENE CORPORATION
To: AMGEN INC.
Reel/Frame 051181/0038 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2014
From: KUMAR, GONDI; MAN, HON-WAH; CHEN, ROGER S.C.; MULLER, GEORGE W.; FRANK, ANTHONY J.
To: CELGENE CORPORATION
Reel/Frame 032587/0592 →
Continuity (2)
Provisional Application 61431350 · Jan 10, 2010
Related Publication 20120178708A1 · Jul 12, 2012